Vitamin e in the prevention of cardiovascular disease: The importance of proper patient selection

Journal of Lipid Research

Volumn 54, Issue 9, 2013, Pages 2307-2314

  Vardi, Moshe ^a,b   Levy, Nina S ^c   Levy, Andrew P ^c  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b CARMEL MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cardiovascular outcomes; Diabetes mellitus; Haptoglobin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; HAPTOGLOBIN; PLACEBO; PRAVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIETARY INTAKE; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FOLLOW UP; GENOTYPE; HEART FAILURE; HEART INFARCTION; HUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT SELECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; VITAMIN SUPPLEMENTATION;

CARDIOVASCULAR OUTCOMES; DIABETES MELLITUS; HAPTOGLOBIN;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; HAPTOGLOBINS; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; VITAMIN E;

EID: 84883167086     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R026641     Document Type: Review

References (76)

1. Wang, X., and P. J. Quinn. 1999. Vitamin E and its function in membranes. Prog. Lipid Res. 38: 309-336.
2. US Department of Agriculture, Agricultural Research Service. 2011. USDA National Nutrient Database for Standard Reference, Release 24. Accessed February 11, 2012. http://www.ars.usda.gov/ba/bhnrc/ndl.
3. Mahoney, C. W., and A. Azzi. 1988. Vitamin E inhibits protein kinase C activity. Biochem. Biophys. Res. Commun. 154: 694-697.
4. Boudreau, R. T., R. Garduno, and T. J. Lin. 2002. Protein phosphatase 2A and protein kinase Calpha are physically associated and are involved in Pseudomonas aeruginosa-induced interleukin 6 production by mast cells. J. Biol. Chem. 277: 5322-5329.
5. Zingg, J. M. 2007. Modulation of signal transduction by vitamin E. Mol. Aspects Med. 28: 481-506.
6. Boscoboinik, D., A. Szewczyk, C. Hensey, and A. C. Azzi. 1991. Inhibition of cell proliferation by alphatocopherol. Role of protein kinase. J. Biol. Chem. 266: 6188-6194.
7. Tasinato, A., D. Boscoboinik, G. M. Bartoli, P. Maroni, and A. Azzi. 1995. d-alpha-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc. Natl. Acad. Sci. USA. 92: 12190-12194.
8. de Nigris, F., F. Franconi, I. Maida, G. Palumbo, V. Anania, and C. Napoli. 2000. Modulation by alpha- and gamma-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells. Biochem. Pharmacol. 59: 1477-1487.
9. Wu, D., L. Liu, M. Meydani, and S. N. Meydani. 2004. Effect of vitamin E on prostacyclin (PGI2) and prostaglandin (PG) E2 production by human aorta endothelial cells: mechanism of action. Ann. N. Y. Acad. Sci. 1031: 425-427.
10. Heller, R., M. Hecker, N. Stahmann, J. J. Thiele, G. Werner- Felmayer, and E. R. Werner. 2004. Alpha-tocopherol amplifies phosphorylation of endothelial nitric oxide synthase at serine 1177 and its short-chain derivative trolox stabilizes tetrahydrobiopterin. Free Radic. Biol. Med. 37: 620-631.
11. Heller, R., G. Werner-Felmayer, and E. R. Werner. 2004. Alphatocopherol and endothelial nitric oxide synthesis. Ann. N. Y. Acad. Sci. 1031: 74-85.
12. Desideri, G., M. C. Marinucci, G. Tomassoni, P. G. Masci, A. Santucci, and C. Ferri. 2002. Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients. J. Clin. Endocrinol. Metab. 87: 2940-2945.
13. Yoshikawa, T., N. Yoshida, H. Manabe, Y. Terasawa, T. Takemura, and M. Kondo. 1998. Alpha-tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors. 7: 15-19.
14. Faruqi R., C. de la Motte, and P. E. DiCorleto. 1994. Alphatocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J. Clin. Invest. 94: 592-600.
15. Yoshida, N., T. Yoshikawa, H. Manabe, Y. Terasawa, M. Kondo, N. Noguchi, and E. Niki. 1999. Vitamin E protects against polymorphonuclear leukocyte-dependent adhesion to endothelial cells. J. Leukoc. Biol. 65: 757-763.
16. Noguchi, N., R. Hanyu, A. Nonaka, Y. Okimoto, and T. Kodama. 2003. Inhibition of THP-1 cell adhesion to endothelial cells by alpha-tocopherol and alpha-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radic. Biol. Med. 34: 1614-1620.
17. Wu, D., T. Koga, K. R. Martin, and M. Meydani. 1999. Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis. 147: 297-307.
18. Koga, T., P. Kwan, L. Zubik, C. Ameho, D. Smith, and M. Meydani. 2004. Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. Atherosclerosis. 176: 265-272.
19. Desideri G., G. Croce, M. C. Marinucci, P. G. Masci, M. Stati, L. Valeri, A. Santucci, and C. Ferri. 2002. Prolonged, low dose alphatocopherol therapy counteracts intercellular cell adhesion molecule- 1 activation. Clin. Chim. Acta. 320: 5-9.
20. van Dam, B., V. W. van Hinsbergh, C. D. Stehouwer, A. Versteilen, H. Dekker, R. Buytenhek, H. M. Princen, and C. G. Schalkwijk. 2003. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc. Res. 57: 563-571.
21. Devaraj, S., and I. Jialal. 2005. Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic. Biol. Med. 38: 1212-1220.
22. Devaraj, S., and I. Jialal. 1999. Alpha-tocopherol decreases interleukin- 1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler. Thromb. Vasc. Biol. 19: 1125-1133.
23. Devaraj, S., D. Li, and I. Jialal. 1996. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J. Clin. Invest. 98: 756-763.
24. Munteanu, A., J. M. Zingg, and A. Azzi. 2004. Anti-atherosclerotic effects of vitamin E-myth or reality? J. Cell. Mol. Med. 8: 59-76.
25. Munteanu, A., M. Taddei, I. Tamburini, E. Bergamini, A. Azzi, and J. M. Zingg. 2006. Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes: involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma. J. Biol. Chem. 281: 6489-6497.
26. Khanduja, K. L., P. K. Avti, S. Kumar, V. Pathania, and C. M. Pathak. 2005. Inhibitory effect of vitamin E on proinflammatory cytokines-and endotoxin-induced nitric oxide release in alveolar macrophages. Life Sci. 76: 2669-2680.
27. Cachia, O., J. E. Benna, E. Pedruzzi, B. Descomps, M. A. Gougerot- Pocidalo, and C. L. Leger. 1998. Alpha-tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47(phox) membrane translocation and phosphorylation. J. Biol. Chem. 273: 32801-32805.
28. Brigelius-Flohé, R. 2009. Vitamin E: the shrew waiting to be tamed. Free Radic. Biol. Med. 46: 543-554.
29. Carr, A. C., B. Z. Zhu, and B. Frei. 2000. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ. Res. 87: 349-354.
30. Blum, S., U. Milman, C. Shapira, and A. P. Levy. 2008. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics. 9: 989-991.
31. Levy, A. P., and S. Blum. 2007. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Rev. Cardiovasc. Ther. 5: 1105-1111.
32. Rimm, E. B., M. J. Stampfer, A. Ascherio, E. Giovannucci, G. A. Colditz, and W. C. Willett. 1993. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328: 1450-1456.
33. Stampfer, M. J., C. H. Hennekens, J. E. Manson, G. A. Colditz, B. Rosner, and W. C. Willett. 1993. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328: 1444-1449.
34. Hennekens, C. H., J. E. Buring, and R. Peto. 1994. Antioxidant vitamins-benefits not yet proved. N. Engl. J. Med. 330: 1080-1081.
35. Buring, J. E., and C. H. Hennekens. 1997. Antioxidant vitamins and cardiovascular disease. Nutr. Rev. 55: S53-S58.
36. Virtamo, J., J. M. Rapola, S. Ripatti, O. P. Heinonen, P. R. Taylor, D. Albanes, and J. K. Huttunen. 1998. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med. 158: 668-675.
37. de Gaetano, G.; Collaborative Group of the Primary Prevention Project. 2001. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 357: 89-95.
38. Sacco, M., F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci. 2003. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 26: 3264-3272.
39. Arad, Y., L. A. Spadaro, M. Roth, D. Newstein, and A. D. Guerci. 2005. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46: 166-172.
40. Hodis, H. N., W. J. Mack, L. LaBree, P. R. Mahrer, A. Sevanian, C. R. Liu, C. H. Liu, J. Hwang, R. H. Selzer, and S. P. Azen. 2002. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 106: 1453-1459.
41. Nanayakkara, P. W., C. van Guldener, P. M. ter Wee, P. G. Scheffer, F. J. van Ittersum, J. W. Twisk, T. Teerlink, W. van Dorp, and C. D. Stehouwer. 2007. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima- media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) study. Arch. Intern. Med. 167: 1262-1270.
42. Lee, I. M., N. R. Cook, J. M. Gaziano, D. Gordon, P. M. Ridker, J. E. Manson, C. H. Hennekens, and J. E. Buring. 2005. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 294: 56-65.
43. Chae, C. U., C. M. Albert, M. V. Moorthy, I. M. Lee, and J. E. Buring. Vitamin E supplementation and the risk of heart failure in women. Circ. Heart Fail. 5: 176-182.
44. Sesso, H. D., J. E. Buring, W. G. Christen, T. Kurth, C. Belanger, J. MacFadyen, V. Bubes, J. E. Manson, R. J. Glynn, and J. M. Gaziano. 2008. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 300: 2123-2133.
45. DeMaio, S. J., S. B. King 3rd, N. J. Lembo, G. S. Roubin, J. A. Hearn, H. N. Bhagavan, and D. S. Sgoutas. 1992. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J. Am. Coll. Nutr. 11: 68-73.
46. Stephens, N. G., A. Parsons, P. M. Schofield, F. Kelly, K. Cheeseman, and M. J. Mitchinson. 1996. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 347: 781-786.
47. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 354: 447-455.
48. Yusuf, S., G. Dagenais, J. Pogue, J. Bosch, and P. Sleight. 2000. Vitamin E supplementation and cardiovascular events in highrisk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342: 154-160.
49. Lonn, E., S. Yusuf, B. Hoogwerf, J. Pogu, Q. Yi, B. Zinman, J. Bosch, G. Dagenais, J. F. Mann, and H. C. Gerstein. 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICROHOPE substudy. Diabetes Care. 25: 1919-1927.
50. Mann, J. F., E. M. Lonn, Q. Yi, H. C. Gerstein, B. J. Hoogwerf, J. Pogue, J. Bosch, G. R. Dagenais, and S. Yusuf. 2004. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int. 65: 1375-1380.
51. Lonn, E., J. Bosch, S. Yusuf, P. Sheridan, J. Pogue, J. M. Arnold, C. Ross, A. Arnold, P. Sleight, J. Probstfield, et al. 2005. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 293: 1338-1347.
52. Waters, D. D., E. L. Alderman, J. Hsia, B. V. Howard, F. R. Cobb, W. J. Rogers, P. Ouyang, P. Thompson, J. C. Tardif, L. Higginson, et al. 2002. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 288: 2432-2440.
53. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 23-33.
54. Boaz, M., S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru, et al. 2000. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 356: 1213-1218.
55. Moreno, P. R., and V. Fuster. 2004. New aspects in the pathogenesis of diabetic atherothrombosis. J. Am. Coll. Cardiol. 44: 2293-2300.
56. Reusch, J. E., and C. C. Wang. 2011. Cardiovascular disease in diabetes: where does glucose fit in? J. Clin. Endocrinol. Metab. 96: 2367-2376.
57. Eckel, R. H., M. Wassef, A. Chait, B. Sobel, E. Barrett, G. King, M. Lopes-Virella, J. Reusch, N. Ruderman, G. Steiner, et al. 2002. Prevention conference VI: diabetes and cardiovascular disease. Writing group II: pathogenesis of atherosclerosis in diabetes. Circulation. 105: e138-e143.
58. Blum, S., M. Vardi, J. B. Brown, A. Russell, U. Milman, C. Shapira, N. S. Levy, R. Miller-Lotan, R. Asleh, and A. P. Levy. 2010. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 11: 675-684.
59. Goyal, T., S. Mitra, M. Khaidakov, X. Wang, S. Singla, Z. Ding, S. Liu, and J. L. Mehta. 2012. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr. Atheroscler. Rep. 14: 150-159.
60. Webster, M. W. 2011. Clinical practice and implications of recent diabetes trials. Curr. Opin. Cardiol. 26: 288-293.
61. Bowman, B. H., and A. Kurosky. 1982. Haptoglobin. The evolutionary product of duplication, unequal crossing over, and point mutation. Adv. Hum. Genet. 12: 189-261.
62. Langlois, M. R., and J. R. Delanghe. 1996. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42: 1589-1600.
63. Kristiansen, M., J. H. Graversen, C. Jacobsen, O. Sonne, H. J. Hoffman, S. K. A. Law, and S. K. Moestrup. 2001. Identification of the haemoglobin scavenger receptor. Nature. 409: 198-201.
64. Bamm, V. V., V. A. Tsemakhovich, M. Shaklai, and N. Shaklai. 2004. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 43: 3899-3906.
65. Melamed-Frank, M., O. Lache, B. I. Enav, T. Szafranek, N. S. Levy, R. M. Ricklis, and A. P. Levy. 2001. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 98: 3693-3698.
66. Levy, A. P., I. Hochberg, K. Jablonski, H. E. Resnick, E. T. Lee, L. Best, and B. V. Howard. 2002. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J. Am. Coll. Cardiol. 40: 1984-1990.
67. Milman, U., S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al. 2008. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective doubleblinded clinical trial. Arterioscler. Thromb. Vasc. Biol. 28: 341-347.
68. Blum, S., M. Vardi, N. S. Levy, R. Miller-Lotan, and A. P. Levy. 2010. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis. 211: 25-27.
69. Levy, A. P., H. C. Gerstein, R. Miller-Lotan, R. Ratner, M. McQueen, E. Lonn, and J. Pogue. 2004. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care. 27: 2767.
70. Roguin, A., W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A. P. Levy. 2003. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care. 26: 2628-2631.
71. Burbea, Z., F. Nakhoul, R. Zoabi, I. Hochberg, N. S. Levy, S. Benchetrit, J. Weissgarten, D. Tovbin, A. Knecht, A. Iaina, et al. 2004. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann. Clin. Biochem. 41: 469-473.
72. Suleiman, M., D. Aronson, R. Asleh, M. R. Kapeliovich, A. Roguin, S. R. Meisel, M. Shochat, A. Sulieman, S. A. Reisner, W. Markiewicz, et al. 2005. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes. 54: 2802-2806.
73. Levy, A. P., P. Friedenberg, R. Lotan, P. Ouyang, M. Tripputi, L. Higginson, F. R. Cobb, J. C. Tardif, V. Bittner, and B. V. Howard. 2004. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care. 27: 925-930.
74. Asleh, R., J. Guetta, S. Kalet-Litman, R. Miller-Lotan, and A. P. Levy. 2005. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ. Res. 96: 435-441.
75. Asleh, R., and A. P. Levy. 2010. Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxid. Redox Signal. 12: 209-217.
76. Costacou, T., R. E. Ferrell, and T. J. Orchard. 2008. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes. 57: 1702-1706.